Moberg Pharma AB (publ)
SSE:MOB.ST
Overview | Financials
Company Name | Moberg Pharma AB (publ) |
Symbol | MOB.ST |
Currency | SEK |
Price | 15.1 |
Market Cap | 422,219,043 |
Dividend Yield | 0% |
52-week-range | 4.133 - 22.8 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Kerstin Valinder Strinnholm |
Website | https://www.mobergpharma.se |
An error occurred while fetching data.
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD